Small Cell Carcinoma of Vulva

Eckert, Franziska; Fehm, Tanja; Bamberg, M.; Müller, Arndt-Christian

doi:10.1007/s00066-010-2160-z

Cited by 17 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preoperative radiotherapy is applied in rectal cancer (Sauer et al, 2012), postoperative treatment in breast cancer (Darby et al). Yet, also rare tumor entities like sarcoma and small cell carcinoma are treated with radiotherapy (Eckert et al, 2010a,b; Muller et al, 2012). Despite modern radiation techniques and advanced multimodal treatments local failures and distant metastases often limit the prognosis, especially due to limited salvage treatments (Muller et al, 2011; Zhao et al, 2012).…”

Section: Radiotherapymentioning

confidence: 99%

Ionizing radiation, ion transports, and radioresistance of cancer cells

Huber¹,

Butz²,

Stegen³

et al. 2013

Front. Physiol.

Self Cite

View full text Add to dashboard Cite

The standard treatment of many tumor entities comprises fractionated radiation therapy which applies ionizing radiation to the tumor-bearing target volume. Ionizing radiation causes double-strand breaks in the DNA backbone that result in cell death if the number of DNA double-strand breaks exceeds the DNA repair capacity of the tumor cell. Ionizing radiation reportedly does not only act on the DNA in the nucleus but also on the plasma membrane. In particular, ionizing radiation-induced modifications of ion channels and transporters have been reported. Importantly, these altered transports seem to contribute to the survival of the irradiated tumor cells. The present review article summarizes our current knowledge on the underlying mechanisms and introduces strategies to radiosensitize tumor cells by targeting plasma membrane ion transports.

show abstract

Section: Radiotherapymentioning

confidence: 99%

Ionizing radiation, ion transports, and radioresistance of cancer cells

Huber¹,

Butz²,

Stegen³

et al. 2013

Front. Physiol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In women with early-stage disease, surgical resection followed by adjuvant chemoradiation is recommended for SCNECs and LCNECs. Primary chemoradiation is commonly proposed for unresectable, locally advanced cases, whereas chemotherapy with or without radiation of the primary tumor is advised in the case of metastatic disease [79,120].…”

Section: Other Gy-necsmentioning

confidence: 99%

Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives

Stumpo,

Formelli,

Persano

et al. 2023

JCM

View full text Add to dashboard Cite

Neuroendocrine carcinomas (NECs) are poorly differentiated and highly aggressive epithelial neuroendocrine neoplasms. The most common primary site is the lung, but they may arise in every organ. Approximately 37% of extrapulmonary NECs (EP-NECs) occur in the gastroenteropancreatic (GEP) tract, followed by the genitourinary (GU) system and gynecological tract. As a result of their rarity, there is scant evidence to guide treatment recommendations, and a multidisciplinary approach is essential for the management of such patients. Platinum-based chemotherapy currently represents the standard of care for EP-NECs of any site, mirroring the management of small-cell lung cancer (SCLC), but further approaches are still under investigation. Indeed, ongoing trials evaluating targeted therapies, immune checkpoint inhibitors (ICIs), and radionuclide therapy could provide potentially breakthrough therapeutic options. Given the relative dearth of evidence-based literature on these orphan diseases, the aim of this review is to provide an overview of the pathology and current treatment options, as well as to shed light on the most pressing unmet needs in the field.

show abstract